HERTHENA-Lung01 is a Phase 2 clinical trial (NCT04619004) aimed at evaluating the anti-tumor activity of patritumab deruxtecan in subjects with metastatic or locally advanced NSCLC and an activating EGFR mutant (exon 19 deletion or L858R). This evidence concerns the gene EGFR and neoplasm.